Clinical Trial

Candidate Clinical Correlate of Prognostic Outcome for TB Study

Study acronym: C3PO
Recruiting
View on ClinicalTrials.gov →
Summary
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-05 -> 2027-05-31 2026-07-21
minor Completion pushed: 2027-05 -> 2027-05-31 2026-07-21
Trial Details
NCT Number NCT07018076
Lead Sponsor University of California, San Francisco
Collaborators: University of California, Irvine, University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Tuberculosis
Enrollment 750 participants
Start Date 2025-11-25
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20